LTZ-301

Phase 1Biologic

LLTZ Therapeutics, Inc.

LTZ-301 is one of 3 biologic programs targeting Non-Hodgkin Lymphoma Refractory/ Relapsed. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Hodgkin Lymphoma Refractory/ RelapsedRecruiting

Non-Hodgkin Lymphoma Refractory/ RelapsedPhase 1

Recruiting

Competition

Competitive Landscape

2 competitors in Non-Hodgkin Lymphoma Refractory/ Relapsed

#DrugCompanyPhaseTrials

BAFF CAR-T

LLuminary Therapeutics

Phase 2

1 2

LTZ-301

LLTZ Therapeutics, Inc.

Phase 1

1 3

CD19 T-Hank

IImmunityBio, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Non-Hodgkin Lymphoma Refractory/ Relapsed

NCT07121946

Clinical

Trials by Indication[1]

Non-Hodgkin Lymphoma Refractory/ Relapsed1 trial

A Phase 1, Open-label, Multicenter Study of LTZ-301 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Recruiting·LLTZ Therapeutics, Inc.·Phase 1·NCT07121946·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LTZ-301. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LTZ-301 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LTZ-301. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — LTZ Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: LLTZ Therapeutics, Inc.

LTZ-301

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Non-Hodgkin Lymphoma Refractory/ Relapsed1 trial

References

Drug Info

Quick Facts

Related News